The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada

Social Science and Medicine

Volumn 34, Issue 9, 1992, Pages 983-991

  Sheingold, Steven ^a   Churchill, David ^b   Muirhead, Norman ^c   Laupacis, Andreas ^d   Labelle, Roberta ^b   Goeree, Ronald ^b  

^a CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d University of Ottowa   (United States)

Author keywords

anemia; cost benefit; end stage renal disease; quality of life

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

BLOOD TRANSFUSION REACTION; CANADA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; COST; COST BENEFIT ANALYSIS; FEMALE; GRAFT SURVIVAL; HEALTH CARE COST; HEMODIALYSIS; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; RANDOMIZATION; TRANSFUSION;

ANEMIA; BLOOD TRANSFUSION; CANADA; DRUG COSTS; ERYTHROPOIETIN; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HOSPITALIZATION; HUMAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGE; QUALITY OF LIFE; RECOMBINANT PROTEINS; RENAL DIALYSIS; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME;

EID: 0026509862     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-9536(92)90129-E     Document Type: Article

References (22)

1. Correction of the anemia end-stage renal disease with recombinant human erythropoietin
2. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin
3. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis
4. Use of erythropoietin in patients with end-stage renal failure
5. Recombinant human erythropoietin treatment in pre-dialysis patients
6. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin
7. Recombinant human erythropoietin: factors to consider in cost-benefit analysis
8. Sensitization and its role in transplantation
9. The highly immunized patient: Kidney transplantation in sensitized patients
10. Factors important to ten year kidney transplant survival
11. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis
12. Special Report: Transfusion risks
13. Transfusion-associated hepatitis and AIDS: What is the risk? (letter)
14. Posttransfusion hepatitis in Toronto Canada
15. Subcutaneous administration of human erythropoietin (r-HuEPO) for treatment of ESRD anemia
16. Efficacy of intravenous and subcutaneous recombinant human erythropoietin therapy in hemodialysis patients
17. Home subcutaneous recombinant human erythropoietin is as effective and safe as given intravenously
18. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis
19. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin
20. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study